Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients-Reference-Cited by-同舟云学术

Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients

Published:2018-05-16 Issue:1 Volume:20 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

Allouchery Violette,Beaussire Ludivine,Perdrix Anne,Sefrioui David,Augusto Laetitia,Guillemet Cécile,Sarafan-Vasseur Nasrin,Di Fiore Frédéric,Clatot Florian^ORCID

Funder

Centre Henri Becquerel

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/s13058-018-0968-0.pdf

Reference11 articles.

1. Chandarlapaty S, Chen D, He W, Sung P, Samoila A, You D, et al. Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial. JAMA Oncol. 2016;2:1310–5.

2. Clatot F, Perdrix A, Augusto L, Beaussire L, Delacour J, Calbrix C, et al. Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor. Oncotarget. 2016;7:74448–59.

3. Fribbens C, O’Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2016;34:2961–8.

4. Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Inao T, Sueta A, Fujiwara S, et al. Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens. Transl Res. 2015;166:540–553.e2.

5. Segal CV, Dowsett M. Estrogen receptor mutations in breast cancer--new focus on an old target. Clin Cancer Res. 2014;20:1724–6.

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Androgen receptor and estrogen receptor variants in prostate and breast cancers;The Journal of Steroid Biochemistry and Molecular Biology;2024-07

2. Current and Upcoming Treatment Strategies After CDK4/6 Inhibitors for Patients With ER+/HER2- Advanced Breast Cancer;EMJ Oncology;2023-12-05

3. ESR1 Gene Mutations and Liquid Biopsy in ER-Positive Breast Cancers: A Small Step Forward, a Giant Leap for Personalization of Endocrine Therapy?;Cancers;2023-10-27

4. Genomic Alterations Associated with Estrogen Receptor Pathway Activity in Metastatic Breast Cancer Have a Differential Impact on Downstream ER Signaling;Cancers;2023-09-04

5. Liquid biopsy: Cell-free DNA based analysis in breast cancer;The Journal of Liquid Biopsy;2023-09